TTD | Drug: D0VA0J

Drug General Information
Drug ID	D0VA0J
Former ID	DNC014623
Drug Name	3,4-Dichloro-N-(3,3-diphenyl-allyl)-benzamide
Drug Type	Small molecular drug
Indication	Discovery agent		Investigative	[527275]
Structure		Download 2D MOL 3D MOL
Formula	C22H17Cl2NO
Canonical SMILES	C1=CC=C(C=C1)C(=CCNC(=O)C2=CC(=C(C=C2)Cl)Cl)C3=CC=CC=C3
InChI	1S/C22H17Cl2NO/c23-20-12-11-18(15-21(20)24)22(26)25-14-13-19(16-7-3-1-4-8-16)17-9-5-2-6-10-17/h1-13,15H,14H2,(H,25,26)
InChIKey	OYXWUVAZLKNOAB-UHFFFAOYSA-N
PubChem Compound ID	44265913
Target and Pathway
Target(s)	Cholecystokinin receptor type A	Target Info	Inhibitor	[527275]
KEGG Pathway	Calcium signaling pathway
	Neuroactive ligand-receptor interaction
	Insulin secretion
	Pancreatic secretion
Reactome	Peptide ligand-binding receptors
Reactome	G alpha (q) signalling events
WikiPathways	GPCRs, Class A Rhodopsin-like
	Gastrin-CREB signalling pathway via PKC and MAPK
	Peptide GPCRs
	GPCR ligand binding
	GPCR downstream signaling
References
Ref 527275	J Med Chem. 1992 Mar 20;35(6):1042-9.Hybrid cholecystokinin-A antagonists based on molecular modeling of lorglumide and L-364,718.
Ref 527275	J Med Chem. 1992 Mar 20;35(6):1042-9.Hybrid cholecystokinin-A antagonists based on molecular modeling of lorglumide and L-364,718.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.

Drug Information